250 related articles for article (PubMed ID: 35834030)
1. Molecular perspective on targeted therapy in breast cancer: a review of current status.
Demir Cetinkaya B; Biray Avci C
Med Oncol; 2022 Jul; 39(10):149. PubMed ID: 35834030
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
3. [New advances in targeted therapy for breast cancer].
Zhao J; Wu N; Zhang SC; Zhao ZW; Li LJ; Liu JT
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):353-361. PubMed ID: 32482023
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
5. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
6. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
Narayanankutty A
Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
[TBL] [Abstract][Full Text] [Related]
7. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Gonzalez-Angulo AM; Blumenschein GR
Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
[TBL] [Abstract][Full Text] [Related]
8. Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer.
Zhang X; Li XR; Zhang J
Curr Cancer Drug Targets; 2013 Feb; 13(2):175-87. PubMed ID: 23215724
[TBL] [Abstract][Full Text] [Related]
9. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
10. [New therapeutical strategies in metastatic hormone-dependent breast cancer].
Vilquin P; Cohen P; Maudelonde T; Tredan O; Treilleux I; Bachelot T; Heudel PE
Bull Cancer; 2015 Apr; 102(4):367-80. PubMed ID: 25799877
[TBL] [Abstract][Full Text] [Related]
11. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer.
Sharma V; Sharma AK; Punj V; Priya P
Semin Cancer Biol; 2019 Dec; 59():133-146. PubMed ID: 31408722
[TBL] [Abstract][Full Text] [Related]
12. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts.
McKenna M; McGarrigle S; Pidgeon GP
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):185-197. PubMed ID: 30318472
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
14. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
Lauring J; Park BH; Wolff AC
J Natl Compr Canc Netw; 2013 Jun; 11(6):670-8. PubMed ID: 23744866
[TBL] [Abstract][Full Text] [Related]
15. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation.
Sharma VR; Gupta GK; Sharma AK; Batra N; Sharma DK; Joshi A; Sharma AK
Curr Pharm Des; 2017; 23(11):1633-1638. PubMed ID: 27848885
[TBL] [Abstract][Full Text] [Related]
17. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
18. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
Austreid E; Lonning PE; Eikesdal HP
Expert Opin Pharmacother; 2014 Apr; 15(5):681-700. PubMed ID: 24579888
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.
Guerrero-Zotano A; Mayer IA; Arteaga CL
Cancer Metastasis Rev; 2016 Dec; 35(4):515-524. PubMed ID: 27896521
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]